Allogene Therapeutics (ALLO) Insider Trading & Ownership

$2.80

-0.11 (-3.78%)

(As of 09/20/2024 ET)

Current Insider Ownership Percentage: 24.30%
Number Of Insiders Buying (Last 12 Months): 2
Amount Of Insider Buying (Last 12 Months): $5.00 M
Number Of Insiders Selling (Last 12 Months): 2
Amount Of Insider Selling (Last 12 Months): $76,536.00

Get ALLO Insider Trade Alerts

Want to know when executives and insiders are buying or selling Allogene Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

ALLO Insider Buying and Selling by Quarter

Ad Behind the Markets

Billionaires Are Betting Big on “Nexus” Technology

TWO firms are already on track to crack the trillion-dollar mark because of this technology. But here's the kicker: I've discovered an under-the-radar play that's currently trading for only $8.

Click here for our #1 "Retirement Window" Stock >>>

Allogene Therapeutics Insider and Congressional Trades History

Transaction Type

Time Frame

Start Date

End Date

Export to Excel

Transaction Date	Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
5/30/2024	Franz B Humer	Director	Sell	11,200	$2.34	$26,208.00
5/16/2024	Arie Belldegrun	Director	Buy	1,724,137	$2.90	$4,999,997.30
1/30/2024	Geoffrey M Parker	CFO	Buy	190	$3.60	$684.00
12/18/2023	Deborah M Messemer	Director	Sell	18,640	$2.70	$50,328.00

(Data available from 1/1/2013 forward)

ALLO Insider Trading Activity - Frequently Asked Questions

: The list of insiders at Allogene Therapeutics includes Alison Moore, Arie Belldegrun, David D Chang, Deborah M Messemer, Eric Thomas Schmidt, Franz B Humer, Geoffrey M Parker, Owen N Witte, Rafael Amado, Stephen Mayo, and Veer Bhavnagri. Learn more on insiders at ALLO.
: 24.30% of Allogene Therapeutics stock is owned by insiders. Learn more on ALLO's insider holdings.
: The following insiders have purchased ALLO shares in the last 24 months: Arie Belldegrun ($4,999,997.30), and Geoffrey M Parker ($684.00).
: Insiders have purchased a total of 1,724,327 ALLO shares in the last 24 months for a total of $5,000,681.30 bought.
: The following insiders have sold ALLO shares in the last 24 months: Deborah M Messemer ($50,328.00), Franz B Humer ($26,208.00), Stephen Mayo ($42,900.00), and Veer Bhavnagri ($83,853.06).
: Insiders have sold a total of 51,442 Allogene Therapeutics shares in the last 24 months for a total of $203,289.06 sold.

Allogene Therapeutics Key Executives

Dr. Arie S. Belldegrun F.A.C.S. (Age 75)
M.D., Co-Founder & Executive Chairman
Compensation: $649.1k
Dr. David D. Chang M.D. (Age 64)
Ph.D., Co-Founder, President, CEO & Director
Compensation: $994.6k
Mr. Joshua A. Kazam (Age 47)
Co-Founder & Director
Compensation: $260.5k
Mr. Timothy L. Moore Ph.D. (Age 63)
Executive VP & Chief Technical Officer
Compensation: $554.35k
Dr. Zachary J. Roberts M.D. (Age 46)
Ph.D., Executive VP of Research & Development and Chief Medical Officer
Compensation: $747.39k
Mr. Geoffrey M. Parker (Age 59)
Executive VP & CFO
Ms. Annie Yoshiyama (Age 40)
Senior VP, Corporate Controller & Principal Accounting Officer
Mr. Earl M. Douglas Esq. (Age 61)
Senior VP, General Counsel, Compliance Officer & Corporate Secretary
Ms. Susan R. Lundeen (Age 58)
Chief People Officer
Ms. Christine Cassiano
Executive VP, Chief Corporate Affairs & Brand Strategy Officer